Literature DB >> 3349651

Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system.

F A Houssiau1, K Bukasa, C J Sindic, J Van Damme, J Van Snick.   

Abstract

We reported recently that a human protein, previously described as IL-1 inducible 26K factor (26K) or interferon-beta 2, was a potent growth factor for B cell hybridomas in vitro. Subsequently, it appeared that this protein was also identical with the lymphokine B cell stimulatory factor 2. Here we report that the levels of 26K are considerably increased during the early stages of acute infections of the central nervous system. This elevation in 26K titres was not observed in either chronic infections or in non-infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349651      PMCID: PMC1541434     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Particle counting immunoassay (PACIA).

Authors:  P L Masson; C L Cambiaso; D Collet-Cassart; C G Magnusson; C B Richards; C J Sindic
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

2.  Interleukin 1 and poly(rI).poly(rC) induce production of a hybridoma growth factor by human fibroblasts.

Authors:  J Van Damme; S Cayphas; G Opdenakker; A Billiau; J Van Snick
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

3.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

4.  Thymus grafts induce B cell development in nude, X-linked immune deficient mice.

Authors:  D Karagogeos; H H Wortis
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

5.  Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.

Authors:  G Haegeman; J Content; G Volckaert; R Derynck; J Tavernier; W Fiers
Journal:  Eur J Biochem       Date:  1986-09-15

6.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.

Authors:  A Zilberstein; R Ruggieri; J H Korn; M Revel
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

8.  B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF).

Authors:  P Poupart; P Vandenabeele; S Cayphas; J Van Snick; G Haegeman; V Kruys; W Fiers; J Content
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

9.  Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.

Authors:  J Van Damme; G Opdenakker; R J Simpson; M R Rubira; S Cayphas; A Vink; A Billiau; J Van Snick
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

10.  Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.

Authors:  J Van Snick; A Vink; S Cayphas; C Uyttenhove
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

  10 in total
  44 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions.

Authors:  Brian C Ward; Sandra Kavalukas; Jamie Brugnano; Adrian Barbul; Alyssa Panitch
Journal:  J Surg Res       Date:  2011-02-23       Impact factor: 2.192

3.  Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain.

Authors:  C J Heyser; E Masliah; A Samimi; I L Campbell; L H Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 4.  Pathogenesis and pathophysiology of bacterial meningitis.

Authors:  A R Tunkel; W M Scheld
Journal:  Clin Microbiol Rev       Date:  1993-04       Impact factor: 26.132

5.  Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.

Authors:  R M Hinson; J A Williams; E Shacter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 6.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15

7.  Immunohistochemical localization of interleukin-6-like immunoreactivity to peripheral nerve-like structures in normal and inflamed human skin.

Authors:  K Nordlind; L B Chin; A A Ahmed; J Brakenhoff; E Theodorsson; S Lidén
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

8.  Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells.

Authors:  M H Wang; H D Flad; W Feist; H Brade; S Kusumoto; E T Rietschel; A J Ulmer
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice.

Authors:  R Faggioni; G Fantuzzi; P Villa; W Buurman; L J van Tits; P Ghezzi
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.